
Four new autoantigens trigger multiple sclerosis
Despite considerable progress in the treatment of multiplesclerosis (MS), the disease still often leads to permanent neurological disability....

Orphan drug developer Minoryx raises €51m
The Series C round was co-led by Columbus Venture Partners and Caixa Capital Risc, and supported by CDTI Innvierte, Fund+, Ysios Capital and other...

Engimmune Therapeutics raises CHF15.5m in seed financing
Pureos Bioventures and Novo Holdings co-led the financing of Engimmune Therapeutics, a spin-off from the research group of Prof. Sai Reddy at the...

BIONtech breaks ground for manufacturing site in Rwanda
According to BioNtech, the facility will be initially equipped with two BioNTainers, and is expected to employ about 100 staff by 2024. However, the...

Ellipses Pharma licences SRB22 from SunRock Biopharma
Under the agreement, British Ellipses Pharma Ltd has been granted global rights to develop and commercialise SBR22 (which it renamed to EP0017) from...

Biotalys’ first proteinbased biocontrol shows up in vineyards
Biotalys, the agricultural Technology (AgTech) company in Ghent (Belgium) and listed at EURONEXT (Euronext - BTLS) is devolping protein-based...

Bayer Leaps to invests €1.3bn externally
"We are on the threshold of a new era of innovation in the life sciences." commented Werner Baumann, Chairman of the Board at Bayer...